Literature DB >> 9720544

Compliance of clinical stage I nonseminomatous germ cell tumor patients with surveillance.

D Hao1, J Seidel, R Brant, F Alexander, D S Ernst, N Summers, J A Russell, D A Stewart.   

Abstract

PURPOSE: We evaluate compliance and its effect on the outcome of patients with clinical stage I nonseminomatous germ cell tumor who underwent post-orchiectomy surveillance at the Tom Baker Cancer Centre.
MATERIALS AND METHODS: From 1980 to 1994, 76 evaluable patients underwent surveillance at the Tom Baker Cancer Centre. The surveillance protocol consisted of clinical evaluation, chest x-ray and serum tumor marker measurements monthly in year 1, every 2 months in year 2, every 6 months in years 3 to 5 and yearly in years 6 to 10. Abdomen and pelvic computerized tomography (CT) were scheduled every 2 months in year 1 and every 4 months in year 2. Noncompliance was defined as missing 2 or more consecutive clinic visits, tumor marker measurements or chest x-rays or 1 or more CT scans.
RESULTS: Compliance with clinical evaluations was 61.5% in year 1 and 35.5% in year 2, whereas compliance with CT was only 25% and 11.8% in years 1 and 2, respectively. By univariate analysis diagnosis before 1990 predicted noncompliance, while age, marital status and distance from the center did not. Recurrent disease was detected in 28 patients (37%) at a median of 5.5 months after orchiectomy (range 1 to 49.5). Among the 47 compliant patients 23 had relapse and none died. Among the 29 noncompliant patients 5 had relapse and 2 died with central nervous system disease.
CONCLUSIONS: Overall compliance with this surveillance program was poor but this study was too small to demonstrate whether poor compliance adversely affects overall survival.

Entities:  

Mesh:

Year:  1998        PMID: 9720544     DOI: 10.1097/00005392-199809010-00038

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  6 in total

1.  Canadian consensus guidelines for the management of testicular germ cell cancer.

Authors:  Lori Wood; Christian Kollmannsberger; Michael Jewett; Peter Chung; Sebastian Hotte; Martin O'Malley; Joan Sweet; Lynn Anson-Cartwright; Eric Winquist; Scott North; Scott Tyldesley; Jeremy Sturgeon; Mary Gospodarowicz; Roanne Segal; Tina Cheng; Peter Venner; Malcolm Moore; Peter Albers; Robert Huddart; Craig Nichols; Padraig Warde
Journal:  Can Urol Assoc J       Date:  2010-04       Impact factor: 1.862

2.  Testis cancer survivors' health behaviors: comparison with age-matched relative and demographically matched population controls.

Authors:  Eileen H Shinn; Richard J Swartz; Bob B Thornton; Philippe E Spiess; Louis L Pisters; Karen M Basen-Engquist
Journal:  J Clin Oncol       Date:  2010-04-05       Impact factor: 44.544

3.  Surveillance policy for Japanese patients with stage I testicular germ cell cancer in the multi-detector computed tomography era.

Authors:  Takeshi Yuasa; Naoko Inoshita; Hajime Tanaka; Shinji Urakami; Shinya Yamamoto; Yasuhisa Fujii; Hitoshi Masuda; Iwao Fukui; Yuichi Ishikawa; Junji Yonese
Journal:  Int J Clin Oncol       Date:  2015-04-18       Impact factor: 3.402

Review 4.  Management of patients with low-stage nonseminomatous germ cell testicular cancer.

Authors:  Andrew J Stephenson; Joel Sheinfeld
Journal:  Curr Treat Options Oncol       Date:  2005-09

5.  High risk NSGCT: case for surveillance.

Authors:  David Michael Kakiashvili; Alvaro Zuniga; Michael A S Jewett
Journal:  World J Urol       Date:  2009-07-16       Impact factor: 4.226

6.  Quality of surveillance for stage I testis cancer in the community.

Authors:  Hua-yin Yu; Rodger A Madison; Claude M Setodji; Christopher S Saigal
Journal:  J Clin Oncol       Date:  2009-08-03       Impact factor: 44.544

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.